Pharmacy AMS interventions can cut inappropriate prescribing, health security body says

An analysis by the UK Health Security Agency found that pharmacy interventions improved antimicrobial stewardship via reductions in inappropriate antibiotic use and good adherence to antimicrobial prescribing guidelines.
A patient consults with a pharmacist at a community pharmacy

Pharmacy antimicrobial stewardship (AMS) interventions among underserved communities reduce inappropriate prescribing and increase uptake of care, but there is still limited evidence around whether the interventions actually reduce disparities in health outcomes, the UK Health Security Agency (UKHSA) has said.

In its report, published on 12 November 2026, UKHSA analysed data from six studies involving pharmacists or pharmacy technicians undertaking interventions around inequalities related to antimicrobial resistance (AMR), infection incidence or antibiotic use and exposure. 

The patient groups in the studies that were analysed in the report included people in rural and underserved communities, Indigenous populations, socio-economically disadvantaged groups, sexual and gender minority populations, older adults, people with multimorbidity, and racial and ethnic minority groups.

Pharmacy professionals “are well placed to address inequalities in AMR through their role in antibiotic prescribing”, the report noted.

The findings of the analysis revealed that pharmacy interventions did improve AMS, with specific improvements including reductions in inappropriate and broad-spectrum antibiotic use, de-escalation of antibiotic use and good adherence to guidelines around antimicrobial prescribing.

The populations in the studies experienced greater knowledge of AMR and improved access to healthcare services, the report highlighted.

However, the report suggested that not many studies actually analysed the links between AMS and the impact on health inequalities or on outcomes around AMR.

“Future research should explicitly evaluate the health equity impacts of pharmacy-led AMS and AMR interventions,” it concluded.

Commenting on the report, Amira Guirguis, chief scientist at the Royal College of Pharmacy, said: “We must address the health inequalities highlighted in the UKHSA report. AMR continues to place a disproportionate burden on some communities, particularly those facing barriers to healthcare. Targeted action is needed to ensure equitable access to timely diagnosis, appropriate treatment, and expert advice is essential if we are to tackle AMR.

“Pharmacy teams play an important role in supporting AMS, improving access to care and helping people manage infections safely. While emerging evidence on pharmacy-led interventions is encouraging, more research is needed to determine their impact on clinical outcomes and their potential to reduce AMR-related inequalities across different population groups.”

The report also said that Pharmacy First accounted for 3.4% of all NHS primary care antibiotic prescribing in 2025.

The supply of antibiotics through Pharmacy First rose in 2025 compared with the first year of the service — rates of supply in 2025 were 53.1% higher than during the first 11 months of the service, which launched in January 2024 — but the report noted an increase in consultations overall within Pharmacy First.

The report also revealed that “the proportion of consultations resulting in an antibiotic supply decreased over this period, suggesting that increased activity was accompanied by proportionally lower antibiotic use” and a “lower rate of antibiotic supply per consultation”.

The data also suggests a “shift in the management of uncomplicated UTIs from general practice to community pharmacies”, it said.

According to the report, the north-east of England saw the highest level of antibiotic consumption in 2025, with 18.2 daily defined doses (DID) per 1,000 inhabitants per day and the lowest consumption in the south-east of England, with 14.1 DID.

However, all regions saw lower total antibiotic use in 2025 compared with  pre-pandemic  2019  and 2024  levels, the report said.

Last updated
Citation
The Pharmaceutical Journal, PJ November 2026, Vol 317, No 8015;317(8015)::DOI:10.1211/PJ.2026.1.439267

    Please leave a comment 

    You may also be interested in